Table 2.

KATHERINE baseline disease characteristics.

TrastuzumabAdo-trastuzumab emtansine
(N = 743)(N = 743)
Histologic subtype, n (%)
 Ductal679 (91.4%)688 (92.6%)
 Lobular38 (5.1%)21 (2.8%)
 Not otherwise specified17 (2.3%)16 (2.2%)
 Other9 (1.2%)18 (2.4%)
Histologic grade, n (%)
 Well differentiated56 (7.5%)57 (7.7%)
 Moderately differentiated263 (35.4%)276 (37.1%)
 Poorly differentiated283 (38.1%)282 (38.0%)
 Unknown141 (19.0%)128 (17.2%)
Primary tumor stage (at surgery), n (%)
 ypT0, ypT1a, ypT1b, ypT1mic, ypT1is306 (41.2%)331 (44.5%)
 ypT1, ypT1c184 (24.8%)175 (23.6%)
 ypT2185 (24.9%)174 (23.4%)
 ypT357 (7.7%)51 (6.9%)
 ypT4, ypT4a, ypT4b, ypT4c9 (1.2%)7 (0.9%)
 ypTd1 (0.1%)5 (0.7)
 ypTXa1 (0.1%)0 (0.0%)
Lymph node stage (at surgery), n (%)
 cN0335 (45.1%)344 (46.3%)
 cN1213 (28.7%)220 (29.6%)
 cN2103 (13.9%)86 (11.6%)
 cN330 (4.0%)37 (5.0%)
 cNXb62 (8.3%)56 (7.5%)
  • aPrimary tumor stage unknown.

  • bLymph node stage unknown.